Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 11, Issue 12, 2005, Pages 1014-1021

  Reddy, Vijay ^a   Winer, Andrew G ^a   Eksioglu, Erika ^a   Meier Kriesche, Herwig Ulf ^a   Schold, Jesse D ^a   Wingard, John R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Graft versus host disease (GVHD); Interleukin 12; Relapse free survival

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; INTERLEUKIN 12; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLUSTER ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RECURRENCE RISK; REFERENCE VALUE; RISK ASSESSMENT; RISK REDUCTION; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-12; LEUKEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 28744440162     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.08.032     Document Type: Article

References (27)

1. Antin JH. Clinical practice. Long-term care after hematopoietic cell transplantation in adults. N Engl J Med. 2002;347:36-42
2. Berthold D, Ghielmini M. Treatment of malignant lymphoma. Swiss Med Wkly. 2004;134:472-480
3. Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease: Pathophysiology, clinical manifestations, and management. Cancer. 2004;101:1936-1946
4. Reddy V, Iturraspe JA, Tzolas AC, et al. Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. Blood. 2004;103:4330-4335
5. Cella M, Scheidegger D, Palmer-Lehmann K, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996;184:747-752
6. Rissoan MC, Soumelis V, Kadowaki N, et al. Reciprocal control helper cell and dendritic cell differentiation. Science. 1999;283:1183-1186
7. Watford WT, Moriguchi M, Morinobu A, O'Shea JJ. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. 2003;14:361-368
8. Brunda MJ, Luistro L, Rumennik L, et al. Interleukin-12: Murine models of a potent antitumor agent. Ann N Y Acad Sci. 1996;795:266-274
9. Grohmann U, Belladonna ML, Bianchi R, et al. IL-12 acts on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. Immunity. 1998;9:315- 323
10. Sykes M, Szot GL, Nguyen PL, Pearson DA. Interleukin-12 inhibits murine graft-versus-host disease. Blood. 1995;86:2429- 243
11. Yang YG, Sergio JJ, Pearson DA, et al. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. Blood. 1997;90:4651-4660
12. The FASTCLUS Procedure. SAS/STAT User's Guide Version 8. Donna M. Sawyer DM, Stokes ME, eds. SAS Publishing. 1999;1193-1244
13. Yang YG. The role of interleukin-12 and interferon-gamma in GVHD and GVL. Cytokines Cell Mol Ther. 2000;6:41-46
14. Mehrotra PT, Wu D, Crim JA, Mostowski HS, Siegel JP. Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J Immunol. 1993;151:2444-2452
15. Ilan Y, Margalit M, Ohana M, et al. Alleviation of chronic GVHD in mice by oral immuneregulation toward recipient pretransplant splenocytes does not jeopardize the graft versus leukemia effect. Hum Immunol. 2005;66:231-240
16. Ji YH, Weiss L, Zeira M, et al. Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses. Bone Marrow Transplant. 2003;32:495-504
17. Jones SC, Murphy GF, Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant. 2003;9:243-256
18. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity or graft-versus-host disease induction due to interferon gammaproduction. Blood. 2001;97:2923-2931
19. Ohata J, Sakurai J, Saito K, et al. Differential graft-versus leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis. Clin Exp Immunol. 2002;129:61-68
20. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versusleukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562
21. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720-1728
22. Marcenaro E, Chiesa MD, Bellora F, et al. IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J Immunol. 2005;174:3992-3998
23. Pelloso D, Cyran K, Timmons L, Williams BT, Robertson MJ. Immunological consequences of interleukin 12 administration after autologous stem cell transplantation. Clin Cancer Res. 2004;10:1935-1942
24. Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med. 2003;349:2201-2210
25. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant. 999; 5:347-356
26. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versushost disease does not require alloantigen expression on host epithelium. Nat Med. 2002;8:575-581
27. Sykes M, Pearson DA, Taylor PA, et al. Dose and timing of interleukin (IL)-12 and timing and type of total-body irradiation: Effects on graft-vs.-host disease inhibition and toxicity of exogenous IL-12 in murine bone marrow transplant recipients. Biol Blood Marrow Transplant. 1999;5:277-284